Temocillin for the Treatment of Urinary Tract Infections: First Italian Data from a Multicentre Real-World Experience.
11 affiliations
- 1Infectious Diseases Unit, University Hospital of Trieste (ASUGI), 34125 Trieste, Italy.
- 2Infectious Diseases Unit, Santa Chiara Hospital, Azienda Sanitaria Universitaria Integrata del Trentino (ASUIT), 38122 Trento, Italy.
- 3Centre for Medical Sciences (CISMed), University of Trento, 38122 Trento, Italy.
- 4Infectious Diseases Unit, Azienda Sanitaria Friuli Occidentale (ASFO), 33170 Pordenone, Italy.
- 5School of Medicine, University of Trieste, 34149 Trieste, Italy.
- 6Urology Unit, Santa Chiara Hospital, Azienda Sanitaria Universitaria Integrata del Trentino (ASUIT), 38122 Trento, Italy.
- 7Pharmacy Unit, Azienda Sanitaria Friuli Occidentale (ASFO), 33170 Pordenone, Italy.
- 8Pharmacy Unit, University Hospital of Trieste (ASUGI), 34125 Trieste, Italy.
- 9Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- 10Microbiology Unit, University Hospital of Trieste (ASUGI), 34149 Trieste, Italy.
- 11Clinical Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy.
Abstract
Background: Temocillin is a narrow-spectrum β-lactam with activity against extended-spectrum β-lactamase (ESBL)- and AmpC-producing Enterobacterales and represents a potential carbapenem-sparing option, especially for urinary tract infections (UTIs). This multicentre study evaluated the real-world use, clinical outcomes, and tolerability of temocillin in Italian clinical practice. Methods: We retrospectively included adults treated with temocillin for UTIs, with or without concomitant bloodstream infection, for at least 5 days at three Italian hospitals between November 2024 and May 2026. Data were collected from electronic medical records. Results: The study included 30 patients. Median age was 51 years (IQR 39-74); 50% presented with sepsis and 40% had UTI-associated bacteraemia. Pyelonephritis was the most common presentation (53.3%). At least one positive culture was obtained in 76.7% of patients, yielding 28 isolates. Of these, 27 were Enterobacterales, and 21/27 (77.8%) were ESBL producers. E. coli accounted for 64.3% of all isolates. Temocillin was administered at 6 g/day in 80% of patients and by continuous infusion in 76.7%. Outpatient parenteral antimicrobial therapy (OPAT) using elastomeric pumps was used in 16.7% of patients. Clinical success at the end of the overall antimicrobial treatment course was achieved in 28/30 patients (93.3%; 95% CI 77.9-99.2%). No recurrence occurred within 30 days, and no treatment-related adverse events directly attributable to temocillin were recorded. Two patients developed Clostridioides difficile infection within 60 days after treatment completion, with no established causal relationship with temocillin. Conclusions: This first Italian multicentre real-world experience reports favourable clinical outcomes with temocillin in UTIs, including in selected patients with sepsis or UTI-associated bloodstream infection, and describes the use of continuous infusion and OPAT in appropriately selected patients.
Related
- The SCOUT agree: nitrofurantoin is safe and effective for first-line treatment of uncomplicated lower urinary tract infections in women.
- Antibiotic treatment of male urinary tract infections: scientific rationale behind the 2026 SPILF guidelines
- Clinical and microbiological determinants of treatment failure in complicated urinary tract infection: a four-hospital cohort of enterobacterales infections in Misurata, Libya
- AFSSAPS recommendations for the management of urinary tract infections in children
- Development and validation of an interpretable prediction model for high-grade vesicoureteral reflux in children with urinary tract infections
BibTeX
@article{benvenuto2026temocillin,
title = {{Temocillin for the Treatment of Urinary Tract Infections: First Italian Data from a Multicentre Real-World Experience.}},
author = {Nicola Benvenuto and Massimiliano Lanzafame and Sergio Venturini and Verena Zerbato and Arianna Perosa and Giovanni Mori and Giovanni Del Fabro and Tommaso Cai and Chiara Zanusso and Filippo Giorgio Di Girolamo and Stefano Colla and Valentina Gerussi and Vasiliki Koumaki and Marina Busetti and Stefano Di Bella},
journal = {Antibiotics (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/antibiotics15101034},
url = {https://europepmc.org/article/MED/42938775},
note = {CC BY},
}
RIS
TY - JOUR
TI - Temocillin for the Treatment of Urinary Tract Infections: First Italian Data from a Multicentre Real-World Experience.
AU - Nicola Benvenuto
AU - Massimiliano Lanzafame
AU - Sergio Venturini
AU - Verena Zerbato
AU - Arianna Perosa
AU - Giovanni Mori
AU - Giovanni Del Fabro
AU - Tommaso Cai
AU - Chiara Zanusso
AU - Filippo Giorgio Di Girolamo
AU - Stefano Colla
AU - Valentina Gerussi
AU - Vasiliki Koumaki
AU - Marina Busetti
AU - Stefano Di Bella
PY - 2026
DA - 2026/10/17
JO - Antibiotics (Basel, Switzerland)
DO - 10.3390/antibiotics15101034
UR - https://europepmc.org/article/MED/42938775
AB - Background: Temocillin is a narrow-spectrum β-lactam with activity against extended-spectrum β-lactamase (ESBL)- and AmpC-producing Enterobacterales and represents a potential carbapenem-sparing option, especially for urinary tract infections (UTIs). This multicentre study evaluated the real-world use, clinical outcomes, and tolerability of temocillin in Italian clinical practice. Methods: We retrospectively included adults treated with temocillin for UTIs, with or without concomitant bloodstream infection, for at least 5 days at three Italian hospitals between November 2024 and May 2026. Data were collected from electronic medical records. Results: The study included 30 patients. Median age was 51 years (IQR 39-74); 50% presented with sepsis and 40% had UTI-associated bacteraemia. Pyelonephritis was the most common presentation (53.3%). At least one positive culture was obtained in 76.7% of patients, yielding 28 isolates. Of these, 27 were Enterobacterales, and 21/27 (77.8%) were ESBL producers. E. coli accounted for 64.3% of all isolates. Temocillin was administered at 6 g/day in 80% of patients and by continuous infusion in 76.7%. Outpatient parenteral antimicrobial therapy (OPAT) using elastomeric pumps was used in 16.7% of patients. Clinical success at the end of the overall antimicrobial treatment course was achieved in 28/30 patients (93.3%; 95% CI 77.9-99.2%). No recurrence occurred within 30 days, and no treatment-related adverse events directly attributable to temocillin were recorded. Two patients developed Clostridioides difficile infection within 60 days after treatment completion, with no established causal relationship with temocillin. Conclusions: This first Italian multicentre real-world experience reports favourable clinical outcomes with temocillin in UTIs, including in selected patients with sepsis or UTI-associated bloodstream infection, and describes the use of continuous infusion and OPAT in appropriately selected patients.
SN - 2079-6382
ER -